Cipla Propels 'Lung Leadership' Plans
Reimagines Operating Models As Q4 Sales Hit By COVID-19
Cipla’s fourth-quarter 2020 sales were hit because of COVID-19- related dispatch challenges, though it remains upbeat about the prospects of interchangeable albuterol and the latest filing for generic Advair Diskus as part of its quest for lung leadership.
You may also be interested in...
Hikma has received another setback on its US application for a generic version of Advair following a minor complete response letter from the FDA. The resulting delay will push back the expected final response date from the agency closer to that expected by rival Cipla, which filed an ANDA earlier this year.
After getting FDA approval in 2018, Teva finally launches its ProAir Digihaler. The company will be making its complete ‘Digihaler’ portfolio available in the US by prescription later this year.
Cipla’s generic equivalent of Migranal is the company’s first nasal spray to receive FDA approval, accompanied by 180 days of competitive generic therapy exclusivity.